Literature DB >> 25888578

Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression.

Tetje C van der Sluis1, Marjolein Sluijter2, Suzanne van Duikeren1, Brian L West3, Cornelis J M Melief4, Ramon Arens1, Sjoerd H van der Burg2, Thorbald van Hall5.   

Abstract

Abundant macrophage infiltration of solid cancers commonly correlates with poor prognosis. Tumor-promoting functions of macrophages include angiogenesis, metastasis formation, and suppression of Th1-type immune responses. Here, we show that successful treatment of cervical carcinoma in mouse models with synthetic long peptide (SLP) vaccines induced influx of cytokine-producing CD8 T cells that strongly altered the numbers and phenotype of intratumoral macrophages. On the basis of the expression of CD11b, CD11c, F4/80, Ly6C, Ly6G, and MHC II, we identified four myeloid subpopulations that increased in numbers from 2.0-fold to 8.7-fold in regressing tumors. These changes of the intratumoral myeloid composition coincided with macrophage recruitment by chemokines, including CCL2 and CCL5, and were completely dependent on a vaccine-induced influx of tumor-specific CD8 T cells. CD4 T cells were dispensable. Incubation of tumor cells with T cell-derived IFNγ and TNFα recapitulated the chemokine profile observed in vivo, confirming the capacity of antitumor CD8 T cells to mediate macrophage infiltration of tumors. Strikingly, complete regressions of large established tumors depended on the tumor-infiltrating macrophages that were induced by this immunotherapy, because a small-molecule drug inhibitor targeting CSF-1R diminished the number of intratumoral macrophages and abrogated the complete remissions. Survival rates after therapeutic SLP vaccination deteriorated in the presence of CSF-1R blockers. Together, these results show that therapeutic peptide vaccination could induce cytokine-producing T cells with strong macrophage-skewing capacity necessary for tumor shrinkage, and suggest that the development of macrophage-polarizing, rather than macrophage-depleting, agents is warranted. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25888578     DOI: 10.1158/2326-6066.CIR-15-0052

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  31 in total

1.  NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.

Authors:  Nadine van Montfoort; Linda Borst; Michael J Korrer; Marjolein Sluijter; Koen A Marijt; Saskia J Santegoets; Vanessa J van Ham; Ilina Ehsan; Pornpimol Charoentong; Pascale André; Nicolai Wagtmann; Marij J P Welters; Young J Kim; Sytse J Piersma; Sjoerd H van der Burg; Thorbald van Hall
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

2.  Active Microneedle Administration of Plant Virus Nanoparticles for Cancer in situ Vaccination Improves Immunotherapeutic Efficacy.

Authors:  Christine E Boone; Chao Wang; Miguel Angel Lopez-Ramirez; Veronique Beiss; Sourabh Shukla; Paul L Chariou; Daniel Kupor; Ricardo Rueda; Joseph Wang; Nicole F Steinmetz
Journal:  ACS Appl Nano Mater       Date:  2020-08-07

Review 3.  Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Authors:  Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief
Journal:  Nat Rev Cancer       Date:  2016-03-11       Impact factor: 60.716

Review 4.  Therapeutic cancer vaccines.

Authors:  Mansi Saxena; Sjoerd H van der Burg; Cornelis J M Melief; Nina Bhardwaj
Journal:  Nat Rev Cancer       Date:  2021-04-27       Impact factor: 60.716

5.  Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.

Authors:  Shin Foong Ngiow; Katrina M Meeth; Kimberley Stannard; Deborah S Barkauskas; Gideon Bollag; Marcus Bosenberg; Mark J Smyth
Journal:  Oncoimmunology       Date:  2015-12-10       Impact factor: 8.110

6.  δ-Catenin peptide vaccines repress hepatocellular carcinoma growth via CD8+ T cell activation.

Authors:  Fei Huang; Junying Chen; Ruilong Lan; Zeng Wang; Ruiqing Chen; Jingan Lin; Lurong Zhang; Lengxi Fu
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

Review 7.  Cancer-Associated Myeloid Regulatory Cells.

Authors:  Yannick De Vlaeminck; Anna González-Rascón; Cleo Goyvaerts; Karine Breckpot
Journal:  Front Immunol       Date:  2016-03-29       Impact factor: 7.561

8.  CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy.

Authors:  Lena M Kranz; Matthias Birtel; Christina Krienke; Christian Grunwitz; Jutta Petschenka; Kerstin C Reuter; Niels van de Roemer; Fulvia Vascotto; Mathias Vormehr; Sebastian Kreiter; Mustafa Diken
Journal:  Hum Vaccin Immunother       Date:  2015-07-17       Impact factor: 3.452

9.  Monocyte-Derived Dendritic Cells Are Essential for CD8(+) T Cell Activation and Antitumor Responses After Local Immunotherapy.

Authors:  Sabine Kuhn; Jianping Yang; Franca Ronchese
Journal:  Front Immunol       Date:  2015-11-23       Impact factor: 7.561

10.  Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours.

Authors:  Lukasz Bialkowski; Alexia van Weijnen; Kevin Van der Jeught; Dries Renmans; Lidia Daszkiewicz; Carlo Heirman; Geert Stangé; Karine Breckpot; Joeri L Aerts; Kris Thielemans
Journal:  Sci Rep       Date:  2016-03-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.